Small molecule inhibitors of DNA-PK for tumor sensitization to anticancer therapy

Area of Science:

• Molecular Biology
• Oncology
• Pharmacology

Background:

• DNA damage response pathways, regulated by phosphatidylinositol 3-kinase-related kinases (PIKKs), are crucial in cancer therapy.
• DNA-dependent protein kinase (DNA-PK) is a key PIKK involved in repairing DNA double-strand breaks through non-homologous end-joining.
• Cancer cell DNA repair capacity influences sensitivity to radio- and chemotherapy; overactivated DNA-PK can lead to treatment resistance.

Purpose of the Study:

• To review small molecule inhibitors targeting DNA-PK as a strategy to enhance cancer therapy.
• To explore the potential of novel compounds in overcoming resistance to conventional and individualized cancer treatments.
• To summarize the in vitro efficacy of these inhibitors in synergizing with radio- and chemotherapy.

Main Methods:

• Review of existing literature on small molecule inhibitors of DNA-PK.
• Analysis of drug properties, including solubility, metabolic stability, and serum half-life.
• Summary of in vitro studies evaluating the synergistic effects of DNA-PK inhibitors with radiotherapy and chemotherapy.

Main Results:

• Current DNA-PK inhibitors face challenges with poor solubility and rapid metabolism in vivo.
• Development of new compounds based on existing drugs is a key strategy to improve efficacy and pharmacokinetic profiles.
• Small molecule inhibitors demonstrate potential in synergizing with radio- and chemotherapy in vitro.

Conclusions:

• Inhibiting DNA-PK is a promising strategy to sensitize cancer cells to therapy and overcome resistance.
• Improving the pharmacokinetic properties of DNA-PK inhibitors is essential for clinical translation.
• Further research into novel small molecule inhibitors is warranted to enhance their efficacy and reduce toxicity in cancer treatment.